December 11th, 2017
jobs
homes

Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Janux Therapeutics, Inc. - Common Stock (NQ:JANX)

16.54 -0.57 (-3.33%)
Streaming Delayed Price Updated: 2:10 PM EST, Dec 4, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Janux Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >
News headline image
Why WestRock Company Are Trading Lower By 13%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session ↗
Gainers Versus Systems Inc. (NASDAQ: VS) surged 270% to $2.26 after the company announced it will partner with Resolve to bring generative AI and gamification to customer payments and credit... 
Via Benzinga
News headline image
Janux Therapeutics Announces Submission of Investigational New Drug Application for JANX008, an EGFR-TRACTr for Solid Tumors
From Janux Therapeutics, Inc.
Via Business Wire
Janux Therapeutics's Return On Capital Employed Overview ↗
 
Via Benzinga
News headline image
Why Janux Therapeutics Shares Rose 33.1% This Week ↗
The clinical-stage biotech company just began its first clinical trial. 
Via The Motley Fool
News headline image
Janux Therapeutics to Present at Upcoming Investor Conferences in November
From Janux Therapeutics, Inc.
Via Business Wire
News headline image
7 Short-Squeeze Stocks for Bold Contrarians to Consider ↗
While market volatility has brough the bears out of hibernation, certain short-squeeze stocks could be a trap for the pessimists. 
Via InvestorPlace
News headline image
Janux Therapeutics Reports Third Quarter 2022 Financial Results and Business Highlights
From Janux Therapeutics, Inc.
Via Business Wire
News headline image
Janux Therapeutics Announces First Patient Dosed with JANX007 in First-in-Human Phase 1 Clinical Trial in Patients with Prostate Cancer
From Janux Therapeutics, Inc.
Via Business Wire
News headline image
7 Short-Squeeze Stocks to Buy for Contrarian Investors ↗
The pessimists may have bitten off more than they can chew for these intriguing contrarian market ideas. 
Via InvestorPlace
News headline image
Janux Therapeutics Appoints Brenda Van Vreeswyk as Head of Human Resources
From Janux Therapeutics, Inc.
Via Business Wire
News headline image
Why NLS Pharmaceutics Shares Tumbled Over 66%; Here Are 68 Biggest Movers From Yesterday ↗
Gainers PepGen Inc. (NASDAQ: PEPG) jumped 110.2% to close at $10.93 after the company announced results from its Phase 1 healthy volunteer trial of PGN-EDO51 for Duchenne Muscular Dystrophy. The trial... 
Via Benzinga
News headline image
Janux Therapeutics Appoints Winston Kung to Board of Directors
From Janux Therapeutics, Inc.
Via Business Wire
News headline image
Why Prothena Corporation Shares Are Trading Higher By 76%, Here Are 53 Stocks Moving In Wednesday's Mid-Day Session ↗
Gainers 
Via Benzinga
News headline image
Janux Therapeutics to Participate and Present at Upcoming Investor Conferences in September
From Janux Therapeutics, Inc.
Via Business Wire
News headline image
Why Minerva Neurosciences Shares Traded Higher By Over 66%; Here Are 78 Biggest Movers From Yesterday ↗
Gainers Minerva Neurosciences, Inc. (NASDAQ: NERV) shares gained 66.5% to close at $7.51 after Point72 Asset Management reported an 8.8% passive stake in the company. 
Via Benzinga
News headline image
Advance Auto Parts, Nordstrom And Other Big Stocks Recording Losses On Wednesday ↗
U.S. stocks closed higher with the Nasdaq Composite gaining 50 points on Wednesday. Here is the list of some big stocks moving lower in the previous session. 
Via Benzinga
News headline image
Janux Therapeutics Reports Second Quarter 2022 Financial Results and Business Highlights
From Janux Therapeutics, Inc.
Via Business Wire
News headline image
Zendesk, Quotient, + 40 Stocks Moving In Friday's Mid-Day Session ↗
Gainers USA Truck, Inc. (NASDAQ: USAK) shares jumped 111% to $30.76. DB Schenker and USA Truck announced plans to combine and create premier North American transportation solutions provider. 
Via Benzinga
News headline image
Looking Into Janux Therapeutics's Return On Capital Employed ↗
According to Benzinga Pro data, during Q1, Janux Therapeutics (NASDAQ:JANX) posted sales of $1.59 million. Earnings were up 0.04%, but Janux Therapeutics still reported an overall loss of $13.41... 
Via Benzinga
News headline image
Janux Therapeutics to Present at 2022 Jefferies Global Healthcare Conference
From Janux Therapeutics
Via Business Wire
News headline image
Janux Therapeutics Announces FDA Clearance of Investigational New Drug Application for JANX007, a PSMA-TRACTr for Metastatic Castration-Resistant Prostate Cancer
From Janux Therapeutics, Inc.
Via Business Wire
News headline image
Janux Therapeutics Reports First Quarter 2022 Financial Results and Business Highlights
From Janux Therapeutics, Inc.
Via Business Wire
News headline image
Janux Therapeutics to Present Preclinical Data at the 18th Annual PEGS Boston for PSMA-TRACTr and EGFR-TRACTr
From Janux Therapeutics
Via Business Wire
News headline image
Janux Therapeutics's Return On Capital Employed Overview ↗
Janux Therapeutics (NASDAQ:JANX) brought in sales totaling $1.62 million during Q4 according to data provided by Benzinga Pro. However, earnings decreased 24.61%, resulting in a... 
Via Benzinga
News headline image
Janux Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2021 Financial Results
From Janux Therapeutics, Inc.
Via Business Wire
News headline image
Janux Therapeutics to Present Virtually at the H.C. Wainwright BioConnect Conference
From Janux Therapeutics, Inc.
Via Business Wire
News headline image
Janux Therapeutics Reports Business Highlights and Third Quarter 2021 Financial Results
From Janux Therapeutics, Inc.
Via Business Wire
News headline image
Janux Therapeutics to Present Virtually at Upcoming Investor Conferences
From Janux Therapeutics, Inc.
Via Business Wire
News headline image
50 Biggest Movers From Yesterday ↗
Gainers Red Cat Holdings, Inc. (NASDAQ: RCAT) shares surged 50% to close at $3.60 on Monday after the company said its subsidiary, Skypersonic, Inc, won a five-year contract from... 
Via Benzinga
News headline image
48 Biggest Movers From Friday ↗
Gainers Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS) shares jumped 135.4% to settle at $5.32 on Friday. The stock possibly traded higher following favorable data results by... 
Via Benzinga
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

More ways to get to us

Lethbridge Herald Facebook Facebook
Lethbridge Herald Twitter Twitter
Lethbridge Herald YouTube YouTube

About Us

Contact the Lethbridge Herald

504 - 7th Street South
Lethbridge, AB T1J 3Z7

[P] (403) 328-4411
[F] (403)328-4536

Print Advertising: (403) 328-4410
National Advertising: (403) 380-7585
Online Advertising: (403) 380-7585
Classifieds: (403) 328-4433

© 1996-2017 The Lethbridge Herald, A Division of Continental Newspapers Canada Ltd.